Radiopharmaceuticals

Lutathera (lutetium (177Lu) oxodotreotide) is a cancer medicine for treating tumours in the gut known as gastroenteropancreatic neuroendocrine tumours (GEP‑NETs). It is a radiopharmaceutical (a medicine that emits a small amount of radioactivity). Lutathera is used to treat GEP-NETs that cannot be removed by surgery, have spread to other parts of the body or are not responding to treatment. Lutathera was designated an 'orphan medicine' (a medicine used in rare diseases) on 31 January 2008. If you are a SAM Nordic customer and wish to order Lutathera, please download the order form, complete it and send to order@samnordic.se Download Lutathera Order Form here